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  Human T-cell leukemia virus type 1 (HTLV-1) induces cell proliferation after 2 
infection, leading to efficient transmission by cell-to-cell contact. After a long latent 3 
period, a fraction of carriers develop adult T-cell leukemia (ATL). In ATL cells, genetic 4 
changes in the tax gene were reported in about 10% of ATL cases. To determine genetic 5 
changes that may occur throughout the provirus, we determined the whole sequences of 6 
HTLV-1 provirus in 60 ATL cases. Abortive genetic changes including deletion, 7 
insertion and nonsense mutations were frequent in all viral genes except in the HBZ 8 
gene, which is transcribed from the minus strand of the virus. G-to-A base substitutions 9 
were the most frequent mutations in ATL cells. Sequence context of G-to-A mutations 10 
was in accordance with the preferred target sequence of human APOBEC3G (hA3G). 11 
Target sequences of hA3G were less frequent in the plus strand of the HBZ coding 12 
region than in other coding regions of HTLV-1 provirus. Nonsense mutations in viral 13 
genes including tax were also observed in proviruses from asymptomatic carriers, 14 
indicating that these mutations were generated during reverse transcription and prior to 15 
oncogenesis. That hA3G targets the minus strand during reverse transcription explains 16 
why the HBZ gene, which is encoded by the minus strand of provirus, is not susceptible 17 
to such nonsense mutations. HTLV-1 infected cells likely take advantage of hA3G to 18 
escape from the host immune system by losing expression of viral proteins.  19 
 3 
INTRODUCTION 1 
  Human T-cell leukemia virus type 1 (HTLV-1) is the causative agent of both adult 2 
T-cell leukemia (ATL) and inflammatory HTLV-1 associated myelopathy/tropical 3 
spastic paraparesis (HAM/TSP) (9, 40). HTLV-1 is a complex retrovirus that encodes 4 
regulatory genes, tax and rex, and accessory genes, p12, p13, and p30 (6, 29). An 5 
accessory gene, HTLV-1 bZIP factor (HBZ), is transcribed from the 3’ long terminal 6 
repeat (LTR) as an anti-sense transcript (10, 47). Previous studies have shown that Tax 7 
expression can immortalize T-lymphocytes in vitro (1, 11), and in vivo the expression of 8 
Tax in transgenic mice causes various tumors depending on the tissue-specific promoter 9 
that expresses Tax (12, 14, 20). In more than half of human ATLs, the tax gene is not 10 
transcribed (41). Three mechanisms have been identified to inactivate Tax expression 11 
(29): 1) abortive genetic changes of the tax gene (7, 41), 2) silencing by DNA 12 
methylation in the 5’LTR (18, 43), and 3) deletion of the 5’LTR (31, 42). Since Tax is a 13 
major target of cytotoxic T-lymphocytes (CTLs) in vivo (17), the tumor cells might 14 
escape from the host immune system by suppressing Tax expression. However, the 15 
actual mechanism used to create genetic changes in the tax gene remains to be 16 
elucidated. Nonsense mutations in the tax gene have also been observed in HTLV-1 17 
carriers and the mechanism to generate these mutations is similarly unknown (8).  18 
  As a host defense against retroviruses, mammalian cells employ the APOBEC3 19 
family, which causes deamination during reverse transcription, resulting in nucleotide 20 
mutations (3, 26). Human APOBEC3G (hA3G) deaminates cytosine residues of 21 
single-stranded DNA during reverse transcription, resulting in high levels of plus-strand 22 
 4 
G-to-A mutations. The human immunodeficiency virus (HIV) nucleocapsid is critical 1 
for incorporation of hA3G into virions (2, 24), while its accessory protein, Vif, 2 
counteracts hA3G. Vif inhibits hA3G packaging into HIV-1 virion through 3 
ubiquitination and proteasomal degradation of hA3G (39, 49). HTLV-1 does not encode 4 
a protein analogous to Vif that inactivates hA3G. Instead, it has been demonstrated that 5 
a domain of the HTLV-1 nucleocapsid suppresses the incorporation of hA3G into the 6 
virion (4). Consistent with this finding, it has been reported that G-to-A mutations are 7 
rare in HTLV-1 carriers (25).  8 
 In this study, we analyzed the sequences of whole proviruses in ATL and carrier cells, 9 
and found that most nonsense mutations in the proviruses were caused by deamination. 10 
The sites of nonsense mutation coincided with the preferred target sequences of hA3G. 11 
In ATL cases, non-sense mutations, deletions and insertions were detected in most of 12 
the viral genes except the HBZ gene, supporting the critical role of the HBZ gene in 13 
ATL.  14 
15 
 5 
MATERIALS AND METHODS 1 
  Cell lines and clinical samples. MT-2 and MT-4 are HTLV-1-transformed cell lines. 2 
MT-1 and TL-Om1 were derived from leukemia cells. Jurkat cells were negative for 3 
HTLV-1. These cells were cultured in RPMI-1640 medium supplemented with 10% 4 
fetal bovine serum, 100 U/ml penicillin, 100 µg/ml streptomycin and 2 mM 5 
L-glutamine at 37˚C under a 5% CO2 atmosphere. Clinical samples were collected from 6 
60 ATL patients and 10 HTLV-1 carriers. Genomic DNA was extracted from peripheral 7 
blood mononuclear cells using standard phenol-chloroform methods. This study was 8 
conducted according to the principles expressed in the Declaration of Helsinki. The 9 
study was approved by the Institutional Review Board of Kyoto University (G204). All 10 
patients provided written informed consent for the collection of samples and subsequent 11 
analysis. 12 
 13 
  Sequencing of complete provirus genomes in ATL cells. The copy number of 14 
HTLV-1 provirus in ATL cases was determined by inverse PCR (5) and ATL samples 15 
with one complete provirus were selected for direct sequencing. The complete provirus 16 
genome was amplified as two halves (fragment I and II) from genomic DNA samples 17 
derived from ATL patients. Fragment I was amplified using primers 18 
5’-TGACAATGACCATGAGCCCCAAATATCC-3’ and 19 
5’-CGGCTATTAAGACCAGGAAG-3’. PCR conditions were as follows: 1 cycle of 20 
94oC for 5 min, 30 cycles of 94oC for 30 s, 64 oC for 30 s and 72 oC for 5 min, 1 cycle of 21 
72 oC for 10 min. Fragment II was amplified using primers 5’- 22 
 6 
AGAAACAAGCTCAGAAGCTA -3’ and 5’- 1 
TGTACTAAATTTCTCTCCTGAGAGTGC-3’. PCR conditions were as follows:  1 2 
cycle of 94oC for 5 min, 30 cycles of 94oC for 30 s, 60 oC for 30 s and 72 oC for 5 min, 1 3 
cycle of 72 oC for 10 min. PCR products were then subjected to nested PCR to amplify 4 
I-1 and I-1 from fragment I, and II-1 and II-2 from fragment II. Primers for I-1 were 5 
5’-TGACAATGACCATGAGCCCCAAATATCC-3’ and 6 
5’-GAGCTTAAAGTGATCTTGG-3’. Primers for I-2 were 7 
5’-TTCCGATAGCCTTGTTCTCA-3’ and 5’-CGGCTATTAAGACCAGGAAG-3’. 8 
Primers for II-1 were 5’-TGGTATTATTTCAAGCTTCC-3’ and 9 
5’-AAATGCAGGAGTTGGGGATT-3’. Primers for II-2 were 10 
5’-AACTGTCTAGTATAGCCATC-3’ and 11 
5’-TGTACTAAATTTCTCTCCTGAGAGTGC-3’. PCR conditions for the nested PCR 12 
were as follows: 1 cycle of 94oC for 5 min, 28 cycles of 94oC for 30 s, X oC for 30 s and 13 
72 oC for 2.5 min, 1 cycle of 72 oC for 10 min. X was 60 oC for I-1 and II-2, 58 oC for 14 
I-2 and II-1. The final PCR products were gel purified and sequence was determined by 15 
direct sequencing.  16 
 17 
  Sequencing of the pol and tax regions in HTLV-1 carriers. Proviral load was 18 
determined as previously reported (32). Herculase II Fusion DNA Polymerase 19 
(Stratagene, La Jolla, CA), a Pfu-based DNA polymerase, was used to amplify pol and 20 
tax regions from genomic DNA derived from HTLV-1 carriers. Primers to amplify the 21 
pol region were 5’- TACACCTTGCAATCCTATGG-3’ and 5’- 22 
 7 
GCTAGGCTTGCCTAGATGGG-3’. PCR conditions were as follow: 1 cycle of 95oC 1 
for 5 min, 30 cycles of 95oC for 20 s, 60 oC for 20 s and 72 oC for 50 sec, 1 cycle of 72 2 
oC for 5 min. Primers to amplify the tax region were 5’- 3 
GGTCCTCCGGGCATGACACA-3’ and 5’- TCTCCACGCTTTTATAGACT-3’. PCR 4 
condition were as follow: 1 cycle of 95oC for 5 min, 28 cycles of 95oC for 20 s, 68 oC 5 
for 20 s and 72 oC for 50 sec, 1 cycle of 72 oC for 5 min. PCR products were purified, 6 
cloned and at least 20 clones sequenced. DNA polymerase fidelity was studied by using 7 
a clone carrying an amplified tax region as template instead of genomic DNA. The tax 8 
region was amplified using the same PCR conditions described above, cloned and 25 9 
clones were sequenced. 10 
 11 
  Sequencing of HTLV-1 genome in non-tumor cells derived from ATL samples. 12 
ATL patient-derived tumor cells are considered a mixture of a major population of 13 
monoclonal expanded tumor cells and a minor population of HTLV-1 infected 14 
non-tumor cells. To amplify the HTLV-1 genome from non-tumor infected cells, ATL 15 
samples carrying defective HTLV-1 genome based on direct sequencing were selected. 16 
Target regions were amplified by setting one of the primers at the deleted region. 17 
Sequences were determined by direct sequencing.  18 
 19 
  Mutation analysis. Nucleotide sequences of all ATL samples were aligned using 20 
GENETYX-MAC Ver.13.0 software. Mutations were determined after filtering for i) 21 
polymorphisms, defined as a nucleotide substitution occurring in >5 cases; ii) linkers, 22 
 8 
defined as >7 common nucleotide substitutions occurring in >2 cases. With these 1 
criteria, the sequence of an ATL case, ATL-25, showed the fewest mutations (3 single 2 
nucleotide substitutions with no deletions or insertions) and was selected as a standard 3 
sequence. The nucleotide positions of identified mutations were numbered relative to 4 
this standard sequence, which has been submitted to the DDBJ (DNA Data Bank of 5 
Japan) database under the accession number AB513134. 6 
   For carrier samples, the sequence of a given region from all clones amplified from a 7 
carrier was aligned and compared with the standard sequence described above with 8 
mutated bases corrected. When a nucleotide substitution occurred in all clones, it was 9 
considered a polymorphism and excluded from the mutation repertoire.  10 
 11 
  cDNA synthesis and quantitative real-time RT-PCR. Total RNA was extracted 12 
from transfectants using Trizol reagent (Invitrogen, Carlsbad, CA). RNA was treated 13 
with DNase I (Invitrogen) to eliminate the genomic DNA. cDNA was synthesized from 14 
1 µg of total RNA with the Superscript preamplification system (Invitrogen) according 15 
to the manufacturer’s protocol. cDNA product was quantified by real-time RT-PCR 16 
with Power SYBR Green PCR Master Mix and 7900HT Fast Real Time PCR System 17 
(Applied Biosystems) according to the manufacturer’s instructions. Specific primers for 18 
hA3G gene were 5’-CGCGTGCCACCATGAAGATC-3’ (forward) and 19 
5’-TGTGGGTGGATCCATCGAGT-3’ (reverse). Specific primers for the human AID 20 
gene were 5’-TTCACCGCGCGCCTCTACTT-3’ (forward) and 21 
5’-GCTGTCTGGAGAGACGAACT-3’ (reverse). Target cDNA was normalized to the 22 
 9 
amount of endogenous mRNA of ACTB. Primers used for ACTB were 1 
5’-AGGCCAACCGCGAGAAGATG-3’ (forward) and 2 
5’-CCAGAGGCGTACAGGGATAG-3’ (reverse). PCRs were carried out in triplicate. 3 
Data was analyzed by the comparative Ct method according to the manufacturer’s 4 
protocols.  5 
 6 
In vitro editing of HTLV-1 genome by hA3G. QT6 quail cells were transfected with 7 
an infectious molecular clone of HTLV-1 (pX1MT-M) (30) in the presence or absence 8 
of hA3G-expression plasmid. Twenty-four hours post-transfection, HTLV-1-producing 9 
QT6 cells were treated with 200 µg/ml of mitomycin C at 37˚C for 30 min, well-washed 10 
and then co-cultivated 1:1 with fresh QT6 cells (13). 72 hours later, cells were collected 11 
and genomic DNA was extracted. hA3G-mediated DNA hypermutation were detected 12 
using 3DPCR that allows differential amplification of G-to-A hypermutants using a Taq 13 
DNA polymerase as previously described (25). The first round of PCR was performed 14 
with a denaturation temperature of 94°C using the primer pair 15 
5'-CTGCAGATACAAAGTTAACC-3' (forward) and 16 
5'-TGGAGGAAGGAGGGTGGAAT-3' (reverse). PCR conditions were 94˚C for 5 min, 17 
followed by 35 cycles of 94˚C for 30 sec, 58˚C for 30 sec and 72˚C for 30 sec, with a 18 
final extension for 10 min at 72˚C. Then, 0.5 µl of the first-round reaction was used as 19 
template for the second round of PCR using the following primers: 20 
5'-CCATGCTTATTATCAGCCCA-3' (forward) and 21 
5'-GTTGGGGGTTGTATGAGTGA-3' (reverse). PCR program was the same as the 22 
 10 
first round of reaction except that the denaturation gradient ranged from 94-82˚C. PCR 1 




  HTLV-1 proviral sequence changes in ATL. Previous studies showed that Tax 2 
expression was frequently lost by genetic changes in the tax gene, by DNA methylation 3 
of the 5’LTR, and by deletion of the 5’LTR (29). Similarly, although not well studied to 4 
date, the expression of other viral proteins might also be lost through genetic changes in 5 
the provirus sequence. To analyze the genetic changes of the HTLV-1 provirus in ATL 6 
cells, we determined the whole sequence of proviruses (9034bp) in 60 ATL cases. For 7 
this study, we chose ATL cases with HTLV-1 proviruses containing both LTRs. As 8 
shown in Table 1, we detected genetic changes (nonsense mutations, deletions and 9 
insertions) in the coding region of viral genes in 28 of 60 ATL cases (46.7%). Deletions 10 
in the proviruses were detected in 27 cases (45%) while insertions were found in 10 11 
cases (16.7%) (See Table S1 in the supplemental material). These deletions and 12 
insertions resulted in the loss or the truncation of protein(s) in 18 cases (Table 1 and see 13 
Table S1 in the supplemental material).  14 
  Nonsense mutations, deletions, and insertions in the viral genes were found in all 15 
viral genes except the HBZ gene (Table 1). Since p30 and p13 use an identical coding 16 
frame, the same mutations generate nonsense changes in both p30 and p13 (Fig. 1). The 17 
frequency of genetic changes in the tax gene was 16.7% (10/60) (Table 1), which was 18 
higher than in previous studies (7, 41). 27 of a total of 29 nonsense mutations 19 
preferentially accumulated in tryptophan codons (27/29: 89.7%) (See Table S2 in the 20 
supplemental material). Since the tryptophan codon is TGG, a G-to-A mutation 21 
generates either a TGA or a TAG stop codon. In one nonsense mutation, the codon for 22 
 12 
arginine (CGA) was converted to the TGA stop codon by a C-to-T mutation. 1 
Interestingly, nonsense mutations tended to accumulate in the same cases (Table 1).  2 
  It was difficult to discriminate between mutations and polymorphisms in provirus 3 
from ATL patients since the proviral sequences in non-leukemic cells could not be 4 
analyzed in most ATL cases without an internal deletion of provirus. Some mutations 5 
might be characteristic of a subgroup of proviruses (polymorphism). Since nonsense 6 
mutations at the tax gene (7469) were detected in 5 ATL cases, we tentatively judged 7 
base substitutions as polymorphisms when more than 5 identical base substitutions were 8 
observed in different cases. Based on this criterion, we observed 591 mutations in all 9 
cases (See Table S3 in the supplemental material). Among them, the G-to-A mutation 10 
was the most frequent, contributing to 28.8% of the total mutations. Other frequently 11 
detected mutations were C-to-T (23.7%), A-to-G (17.1%) and T-to-C (12.9%). Frequent 12 
G-to-A and C-to-T mutations strongly suggested the activity of deamination enzymes in 13 
the generation of these mutations.  14 
 15 
  Mutations in leukemic and non-leukemic cells in ATL cases. In ATL patients, 16 
non-leukemic HTLV-1 infected cells co-exist with leukemic cells. To analyze the 17 
proviral sequences of non-leukemic cells, we amplified proviral sequences using 18 
primers within regions deleted in leukemic cells to avoid amplification of provirus from 19 
leukemic cells. Nonsense mutations that were observed in leukemic cells were not 20 
detected in non-leukemic cells (Fig. 2), indicating that nonsense mutations generated in 21 
the provirus of leukemic cells were selected for. We compared the whole sequences of 22 
 13 
HTLV-1 provirus in both leukemic cells and non-leukemic cells from five ATL cases. 1 
As shown in Table 2, only 37% of base substitutions were considered to be real 2 
mutations since the nucleotide differed between leukemic cells and non-leukemic cells. 3 
However, 71% of G-to-A transitions were actually mutations while 73% of other base 4 
substitutions were polymorphisms (Table 2), indicating that G-to-A mutations are 5 
predominant in ATL cells.  6 
  Association of G-to-A mutations with human APOBEC3G. A high frequency of 7 
G-to-A mutations suggests the role of deaminase(s) in generating these mutations. 8 
Deamination enzymes are known to have individually preferred target sequences for 9 
deamination (44). Sequences surrounding the nonsense mutations generated by the 10 
G-to-A mutation in HTLV-1 proviruses showed a predominance of the 5’-GG 11 
dinucleotide context (target underlined) (Fig. 3A). Among trinucleotides containing GG 12 
dinucleotides, CGG, TGG and GGG were preferred (Fig. 3A); these are consistent with 13 
the target sequences of hA3G (48). The AGG sequence was also targeted in HTLV-1, 14 
unlike in HIV-1. When we checked tetrameric sequences that contain a central GG 15 
dinucleotide, CGGG and TGGG were the preferred targets in the HTLV-1 provirus, 16 
similar to those reported for HIV-1 (Fig. 3B). As in HIV-1, a C at the +2 position 17 
(NGGC) was disfavored in HTLV-1. These findings suggest that the observed G-to-A 18 
mutations were generated by hA3G. Another deaminase, APOBEC3F (hA3F), which is 19 
largely coexpressed with hA3G, is also reported to target single-stranded minus DNA 20 
(46). Unlike hA3G, which favors the 5’-GG dinucleotide, the consensus target sequence 21 
of hA3F is 5’-GA (21). G-to-A mutations at GA sites contributed 13.4% of all G-to-A 22 
 14 
mutations (Fig. 3A), suggesting that hA3F might also play a role in these mutations in 1 
the HTLV-1 provirus.  2 
  Since hA3G targets the minus strand during reverse transcription, nonsense mutations 3 
generated by G-to-A mutations are not found in the HBZ gene. A G-to-A mutation in 4 
the proviral sense strand caused a nonsense mutation in the p12 gene (TGG to TGA), 5 
whereas the same mutation generated a missense mutation in the HBZ gene (CCA to 6 
TCA) (Fig. 1). G-to-A mutations occurred most frequently at GG sites with a T or C at 7 
their 5’ terminus (Fig. 3A). We therefore counted the TGG or CGG sites within 8 
individual HTLV-1 regions (Table 3). As NGGC (N indicates T or C) was disfavored 9 
by hA3G (Fig. 3B), it was not included. Among HTLV-1 regions, the plus-strand 10 
sequence of the HBZ gene had the fewest TGG and CGG sites, even when the number 11 
of sites was normalized by size of the region. This indicates that mutations in the HBZ 12 
gene-coding region caused by hA3G are also rare.  13 
 14 
  Mutations in the HTLV-1 proviral sequences from carriers. Frequent detection of 15 
G-to-A mutations in HTLV-1 proviral sequences in ATL cases suggests that these 16 
nonsense mutations potentially occur in both HTLV-1 carriers and ATL patients. To 17 
explore this possibility, we next studied the proviral sequences (pol, env, p12, p13/p30, 18 
p27, tax, and HBZ) in asymptomatic HTLV-1 carriers. The proviral sequences in 19 
asymptomatic carriers were amplified using a high fidelity DNA polymerase with 20 
proofreading activity, and after subcloning, the sequences were determined for at least 21 
20 subclones. As seen in ATL cases, the mutation frequency differed drastically among 22 
 15 
individual carriers (representative data are shown in Table S4 and S5 in the 1 
supplemental material), and the distribution of base substitutions among clones varied 2 
within individual carriers. G-to-A mutations accounted for 81% and 72 % of all 3 
mutations in the pol and the tax genes, respectively (Table 4 and 5). High frequency of 4 
G-to-A mutations was also observed in other viral genes (data not shown). Analyses of 5 
the sequence context of G-to-A mutations showed a predominance of GG sequences, 6 
which is consistent with the finding that hA3G deaminates the viral genome during 7 
reverse transcription (48). In order to compare the frequencies of nonsense mutations in 8 
carriers versus ATL cases, the occurrence of nonsense mutations was further analyzed. 9 
Consistent with findings in ATL cases, nonsense mutations were detected in the pol, 10 
env, p30/p13, p27 and tax genes, but not in the p12 or HBZ genes (Table 6). As in ATL 11 
cases, nonsense mutations in carriers were most frequently observed in the tax and pol 12 
genes. This result suggests that there is no bias for mutations in specific viral genes in 13 
ATL cases compared with carriers. These results suggest that nonsense mutations in 14 
provirus are not generated during oncogenesis, but are present in the carrier state.  15 
 In addition to G-to-A mutation, C-to-T mutations were detected in the pol and tax 16 
genes in carrier cells as in ATL cells (See Table S2 in the supplemental material) as 17 
well as other viral regions (data not shown). Comparative analyses of leukemic cell and 18 
non-leukemic cells showed that 79% of C-to-T base substitutions were polymorphisms 19 
(Table 2). However, after G-to-T mutations, C-to-T mutations were still the most 20 
frequent in ATL patients and HTLV-1 carriers.  21 
 22 
 16 
  Expression of the hA3G gene and activation-induced deaminase gene 1 
In order to analyze the correlation between G-to-A mutation and hA3G expression, we 2 
first studied the mRNA level of hA3G using real-time PCR assay. The hA3G gene was 3 
expressed in normal T cells and the expression level of hA3G moderately decreased in 4 
ATL cells. In ATL samples, there was no obvious correlation between the expression 5 
level of hA3G and number of G-to-A mutations in the proviral genome.  6 
 Although only 21% of C-to-T base substitutions were mutations (Table 2), C-to-T was 7 
the second most frequent mutation (See Table S2 in the supplemental material). 8 
Activation-induced deaminase (AID) was found to be a key factor for the switch 9 
recombination of immunoglobulin (Ig), and is also implicated in hypermutations of Ig 10 
genes (15). AID deaminates cytosine to uracil. Aberrant expression of AID driven by 11 
NF-κB activation is found in gastric cancers and hepatomas, and AID expression has 12 
been invoked to explain induced mutations observed in cancer cells (28). Therefore, we 13 
studied AID expression in 7 ATL cases with different proviral mutation frequencies. As 14 
shown in Fig.4, the AID gene transcription increased in ATL-15. In this case, we found 15 
six C-to-T mutations in the provirus, and the sequence context showed more AID 16 
preferred sequences in C-to-T mutated sites compared to other cases without AID 17 
activation (data not shown). Thus, AID might also play a role in the deamination of the 18 
HTLV-1 genome in at least some ATL cases. Since AID is thought to target double 19 
strand DNA of provirus, it likely generates C-to-T mutations in the plus strand of 20 
provirus. However, C-to-T base substitutions contained many polymorphism, as shown 21 
in Table 2. Therefore, correlation between C-to-T mutations and AID expression 22 
 17 
remains to be studied.  1 
 2 
In vitro editing of the HTLV-1 genome by hA3G 3 
Previous reports have suggested that HTLV-1 is relatively resistant to the antiviral 4 
effect of hA3G (4), consistent with our finding that the frequency of G-to-A mutations 5 
throughout the HTLV-1 proviral genome was low. In order to provide direct evidence 6 
that G-to-A mutations observed in the proviruses are the result of hA3G-mediated 7 
genome editing, we studied in vitro the editing effect of hA3G on the HTLV-1 genome. 8 
HTLV-1 viruses were generated in the presence of exogenous hA3G to allow packaging 9 
into budding viral particles, a step that is required for exerting editing activity of the 10 
cytidine deaminase. After a round of virus infection, the HTLV-1 DNA was analyzed 11 
using a highly sensitive PCR-based protocol, referred to as 3D PCR, that is capable of 12 
amplifying G-to-A hypermutated genomes as described in the Materials & Methods. 13 
Differential amplification of a tax region from cells infected with viral particles 14 
produced in the presence of hA3G was achieved when the denaturation PCR 15 
temperature was lowered to between 84-86˚C (data not shown). All sequences of 16 
differentially amplified PCR clones exhibited extensive G-to-A hypermutation, and the 17 
number (percentage) of G-to-A transitions ranged from 8 (13%) to 29 (48%) per clone 18 
(Fig. 5). In ATL cases in the same region, G-to-A mutations at four nucleotide positions 19 
resulted in premature stop codons in the p30 and tax genes (Fig. 1). The occurrence of 20 
such mutations was observed in vitro when viruses were produced together with hA3G. 21 
G-to-A mutations at two sites, in which nonsense mutations were more frequently 22 
 18 
detected in ATL cases, were also frequent among 3D PCR clones. As expected, a 1 
preference for GG dinucleotide context in hA3G-mediated G-to-A editing was observed 2 
(Fig. 5C). Our data suggested that hA3G is indeed able to actively deaminate HTLV-1 3 
viral genome during reverse transcription although with low editing frequency, leading 4 




  In this study, in order to acquire a full mutation spectrum of HTLV-1 virus, 2 
sequences of proviral genomes were determined in 60 ATL cases as well as 10 3 
asymptomatic carriers. In addition to deletion and insertion, we identified base 4 
substitutions, and found that G-to-A mutations were most prevalent. In addition to the 5 
observation that G-to-A mutations in ATL and carriers occurred at the preferred target 6 
sequence of hA3G, we also experimentally confirmed that hA3G actively introduced 7 
G-to-A mutations to the HTLV-1 viral genome. It has been reported that hypermutation 8 
in the HTLV-1 genome was a rare event (35), and HTLV-1 was relatively resistant to 9 
the antiviral activity of hA3G (33). Unlike HIV, which counteracts hA3G by producing 10 
Vif, HTLV-1 does not express an accessory protein that interferes with hA3G. A 11 
peptide motif in the C-terminus of the HTLV-1 nucleocapsid has been shown to inhibit 12 
hA3G packaging into nascent virions (4). However, inhibition of hA3G induced G-to-A 13 
mutations by HTLV-1 was partial (37). Previous studies analyzed small regions of 14 
provirus amplified by PCR in carriers or HAM/TSP patients, while proviral sequences 15 
of ATL cells were determined by direct sequencing. Since previous studies used 16 
error-prone Taq polymerase, it was very difficult to identify mutations after cloning (36). 17 
The number of ATL cases was so limited in the previous studies that mutations could 18 
not be discriminated from polymorphisms (34). This study first analyzed the whole 19 
sequence of 60 ATL cases by direct sequencing, and also determined the proviral 20 
sequences of clones derived from HTLV-1 carriers using a precise DNA polymerase, 21 
which enabled us to identify mutations in HTLV-1 genomes. Consistent with previous 22 
 20 
studies (34, 35), our results showed that mutations were relatively rare. However, 1 
among the rare mutations in HTLV-1 genomes, G-to-A mutations in the target 2 
sequences of hA3G were predominant. In addition to G-to-A mutations, other mutations 3 
were also observed in ATL and carriers, indicating the role of other deaminases 4 
including AID and error-prone reverse transcriptase (27).  5 
  This study demonstrated important roles for cytidine deaminase(s) in generating 6 
mutations in HTLV-1 proviruses. So far, at least 12 cytidine deaminases have been 7 
identified, many of which share significant sequence homology. They are considered to 8 
have evolved through gene transpositions and duplications (45). Although some 9 
members, including APOBEC1 and AID, target cellular genes, most human APOBEC 10 
proteins are thought to defend the host against retroviruses. Our study suggests that 11 
hA3G is responsible for G-to-A mutations in HTLV-1. hA3G binds to single-stranded 12 
DNA, and preferentially deaminates CCCA or CCCG sequences during reverse 13 
transcription (48). This strategy of hA3G can induce nonsense mutations in the 14 
plus-strand coding sequence since TGG is a target of hA3G, resulting in nonsense 15 
mutations like TAG or TGA. However, the HBZ gene is encoded by the minus strand of 16 
the provirus. The HBZ gene is therefore much less susceptible to nonsense mutations 17 
generated by hA3G. Furthermore, there are few target sequences for hA3G in the plus 18 
strand of the HBZ coding RNA. In addition, the coding sequence of the HBZ gene 19 
overlaps that of p12 gene. Thus, HBZ further avoids missense mutation in the minus 20 
strand.  21 
 The frequencies of G-to-A changes in the HTLV-1 provirus (0.21% for the pol gene 22 
 21 
and 0.11% for the tax gene) in the carriers are slightly lower than that for vif positive 1 
HIV-1 (0.57%) (48), indicating that HTLV-1 is resistant to hA3G during reverse 2 
transcription. Why are the few nonsense mutations that do occur retained in the 3 
HTLV-1 provirus? The difference between HTLV-1 and HIV-1 is related to their 4 
distinct strategies of propagation. HIV-1 replicates vigorously in vivo, producing 5 
tremendous numbers of viral particles. Viruses with nonsense mutations cannot 6 
replicate, and thereby disappear in vivo. On the other hand, HTLV-1 promotes the 7 
proliferation of the infected cells themselves by the action of its regulatory and 8 
accessory genes. Therefore, HTLV-1 infected cells can proliferate despite nonsense 9 
mutations occurring in most of the viral genes, provided the cells retain the minimum 10 
set of viral genes that relate to proliferation. This might be a reason why so many 11 
nonsense mutations in various viral genes remain in the provirus. The only gene without 12 
nonsense mutation is HBZ. It is likely that the HBZ gene is indispensable for 13 
proliferation of ATL cells, as our previous studies reported (38).  14 
  Previous studies suggest that Tax is critical for proliferation of HTLV-1 infected cells 15 
and oncogenesis. However, we reported that Tax expression is frequently disrupted by 16 
three mechanisms (29). It has been speculated that Tax expression is not necessary in 17 
the late stages of ATL. Rather, since Tax is a major target of CTLs, ATL cells without 18 
Tax expression are selected during leukemogenesis. However, as shown in this study, 19 
nonsense mutations were likely generated by hA3G during reverse transcription , 20 
indicating that Tax expression was not necessary even in the carrier state. In one carrier, 21 
9 of 21 clones shared a nonsense mutation in the tax gene, demonstrating clonal 22 
 22 
expansion of HTLV-1 infected cells with this mutation (Table S5). Furthermore, 7 of 60 1 
ATL cases contained nonsense mutations in the tax gene. HTLV-1 infected cells with 2 
nonsense mutations could proliferate in vivo and be transformed to ATL cells. A 3 
nonsense mutation in the tax gene has been detected in asymptomatic carriers (8). This 4 
study suggests that this nonsense mutation was generated by hA3G during reverse 5 
transcription. Another explanation is that loss of the expression of some viral gene(s) by 6 
nonsense mutations benefits the cells. Tax generates DNA damage that activates 7 
checkpoints (16, 22). In addition, it has been reported that HTLV-1-infected cells 8 
become cell cycle-arrested due to the activity of Tax (19, 23). Therefore, HTLV-1 9 
infected cells with nonsense mutations in the tax gene might have growth-advantage by 10 
loosing Tax expression. We previously reported that HTLV-1 provirus lacking the 11 
5’LTR and the second exon of the tax gene was detected in ATL cases. By sequencing 12 
the integration sites in such defective provirus, we found 6 bp short repeats generated by 13 
integrase. This finding showed that defective proviruses that could not produce Tax 14 
were generated before integration (31). Taken together, these findings indicate that Tax 15 
is not necessary for oncogenesis at least in some ATL cases.  16 
  This study suggests that nonsense mutations in the HTLV-1 provirus are generated by 17 
hA3G in both ATL cases and HTLV-1 carriers. That hA3G targets the minus strand 18 
during reverse transcription explains why the HBZ gene is not susceptible to such 19 
nonsense mutations. On the contrary, HTLV-1 infected cells take advantage of hA3G to 20 
escape from the host immune system by losing expression of other viral proteins, while 21 
the HBZ gene remains intact.  22 
 23 
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FIGURE LEGENDS 1 
Fig. 1. Schema of the distribution of nonsense mutations in HTLV-1 provirus. The 2 
p13 gene has the same reading frame as the p30 gene. A star indicates a nonsense 3 
mutation observed in an ATL case.  4 
 5 
Fig. 2. Mutations in non-tumor cell-derived proviral sequence in ATL patients. 6 
HTLV-1 genomes from two ATL samples with internal deleted regions were 7 
schematically demonstrated. As indicated by horizontal arrows, one of the PCR primers 8 
was set in the deleted region in order to specifically amplify a proviral region originated 9 
from non-tumor cells (See Materials & Methods). Nested PCR products, represented by 10 
short lines, were subject to direct sequencing. Nucleotide bases mutated in tumor cells 11 
according to the criteria mentioned in Materials & Methods were displayed. A base 12 
substitution is considered as a polymorphism if the same base was found also in the 13 
non-tumor cells derived from the same patient sample. Positions underlined are those at 14 
which a G-to-A mutation will result in a nonsense mutation.  15 
 16 
Fig. 3. Target sequence preference of G-to-A mutations. (A) Sequence context of 17 
G-to-A mutations. In all G-to-A mutations, the percentage of ones at the indicated 18 
dinucleotide sequence context is shown (left panel). In GG context, the influence of 5’ 19 
(middle panel) and 3’ (right panel) nucleotides neighboring the GG dinucleotide on 20 
G-to-A mutations is displayed. (B) Frequency of G-to-A mutations on sites of 21 
tetranucleotides containing a central GG. HTLV-1 genome sequence from ATL-25 was 22 
 29 
used as a standard sequence with mutated bases corrected to calculate the total number 1 
of GG sites that exist in the provirus genome (See Materials & Methods). The 2 
percentage of GG sites that underwent G-to-A mutation for at least once in 60 ATL 3 
cases was plotted against each sequence context. Mutated bases are underlined. CGGG 4 
and TGGG were the preferred targets for G-to-A mutation in the HTLV-1 provirus. A C 5 
at the +2 position (NGGC) was disfavored. 6 
 7 
Fig. 4. Expression of the hA3G and AID gene in ATL cases and in HTLV-1 8 
associated cell lines. Expression of the hA3G (A) and AID gene (B) was investigated 9 
by real-time PCR. Normal resting T cells isolated from 3 healthy blood donors were 10 
used as a control. ACTN was used as an internal control. Relative quantification was 11 
performed using a comparative Ct method (Applied Biosystems). Expression of hA3G 12 
and AID in resting T cells was artificially set as 1. Number of nucleotide mutations in 13 
the 7 ATL cases was shown below. Among mutated sites, number of AID preferred 14 
sites was demonstrated in parenthesis. (C) Number of nucleotide mutations in the 7 15 
ATL cases. Among mutated sites, the number of AID preferred sites was demonstrated 16 
in parenthesis. 17 
 18 
 19 
Fig. 5. In vitro editing of HTLV-1 genome by hA3G. (A) Mutation matrix for 20 
hyperedited tax gene sequences derived from cloned 86˚C 3DPCR products. n indicates 21 
the number of bases sequenced. (B) A selection of hypermutated HTLV-1 tax sequences 22 
 30 
from tissue culture. The sequence is given with respect to the viral plus strand. Only 1 
differences are shown. # and % denotes respectively the number of mutations and the 2 
percentage of G-to-A transitions per sequence. The base composition of the sequence is 3 
75 T (24 %), 113 C (36.2 %), 60 G (19.2 %) and 64 A (20.5 %). Position number of the 4 
first base is indicated above the base. Arrows indicate positions where G-to-A-mediated 5 
nonsense mutations were detected in ATL cases. (C) Bulk dinucleotide context of 6 
HTLV tax region DNA strand by hA3G. The ordinate represents the substitution 7 
frequency as a function of the 3' nucleotide. Mutated G residues are underlined. A χ2 8 
analysis showed that the observed frequencies by hA3G deviated significantly from the 9 
expected values (p < 0.001).10 
 31 
1 
Table 1. Abortive genetic changes of HTLV-1 viral genes in 60 ATL casesa  
  gag  pol env p12 p30 p13 p27 tax HBZ 
ATL-2  DEL        
ATL-3        W248*  
ATL-7   DEL       
ATL-8   DEL    W139*   
ATL-10 DEL DEL DEL       
ATL-11  W680* W427*       
ATL-12 DEL  W387*  W165* W11* W139* W56*  
ATL-13 W59* W680* DEL  W165* 
 
W11*  W56*  
     W190* W36*    
ATL-14       DEL DEL  
ATL-15  W680*        
ATL-27  DEL        
ATL-29   W431*  W165* W11*  W56*  
ATL-32  W271*        
ATL-36        DEL  
ATL-37  W485* W50*     W56*  
  W680*        
ATL-39    W87*      
ATL-40     R184* R30*    
ATL-41  W485*      W56*  
ATL-42   DEL       
ATL-43  DEL        
ATL-44 DEL DEL  W87*      
ATL-45 DEL       Y286*  
ATL-46 DEL DEL        
ATL-47 DEL DEL        
ATL-48 DEL       IN  
ATL-49 DEL DEL        
ATL-51     W178* W24*    
ATL-53 DEL                 
aOnly cases with deletion, insertion or non-sense mutations are shown. DEL, deletion. 





Table 2. Concordance rate of mutations between leukemic cells and non-leukemic cells 
in five ATL cases. 
  Totala G-A C-T A-G T-C A-C A-T C-G C-A T-G G-C G-T T-A 
ATL-8 10 (4) 2 (1) 3 (1) 2 (0) 1 (0) - - 1 (1) - - 1 (1) - - 
ATL-12 25 (8) 8 (6) 7 (2) 5 (0) 3 (0) - - 2 (0) - - - - - 
ATL-13 36 (20) 10 (8) 8 (3) 7 (2) 2 (1) 2 (0) - - 1 (0) 1 (0) 3 (3) 1 (0) 1 (0) 
ATL-14 12 (2) 1 (1) 7 (0) 1 (0) 2 (0) - - - 1 (1) - - - - 
ATL-45 16 (3) 3 (1) 3 (0) 4 (0) 2 (1) - 3 (0) - 1 (1) - - - - 
Total 99 (37) 24 (17) 28 (6) 19 (2) 10 (2) 2 (0) 3 (0) 3 (1) 3 (2) 1 (0) 4 (4) 1 (0) 1 (0) 
Concordance rate (%) 37% 71% 21% 11% 20% 0% 0% 33% 67% 0% 100% 0% 0% 
Each entry A(B) shows the number A of each type of mutation in ATL judged by our 
criteria and the number B of confirmed mutations. Concordance rate of mutations was 
calculated by dividing B by A.  
aNumber of mutations of all types in each ATL case. 
 33 
Table 3. Distribution of hA3G target sequence in the plus strand of HTLV-1 genome. 
Genome Regions 5'LTR gag pol env p27 p30 tax HBZ 3'LTR 
Size (bp) 755 1290 2691 1467 570 726 1062 621 755 
CGGXa 8 12 16 8 3 2 5 1 7 
CGGX/1 kb 10.60 9.3 5.95 5.45 5.26 2.75 4.71 1.61 9.27 
TGGX 3 10 25 17 10 7 11 1 3 
TGGX/1 kb 3.97 7.75 9.29 11.59 17.54 9.64 10.36 1.61 3.97 
aX indicates A, T or G. 
 34 
Table 4. Mutations in the pol region of 10 HTLV-1 carriersa  
  Number and type of single nucleotide substitution   Sequence context of G-to-A mutations 
  G-A C-T A-G T-C A-C C-G G-C G-T T-A  GA GC GT GG 
C72 (25) 5 1     1       5 
C79 (20) 8  1  1   1   1 1  6 
C63 (28) 1       1     1  
C40 (26) 13  1           13 
C32 (22)  2             
C62 (22) 1 2            1 
C87 (22) 14          1 1  13 
C5 (23) 19 1      1 2     19 
C29 (25) 9     1  1    1  8 
C82 (27) 7     1               1   6 
Total 77 6 2 1 1 1 1 4 2  2 4 1 71 
aNumber of clones studied for each samples was indicated in the brackets. Mutated 
bases are underlined. 
 
 35 
Table 5. Mutations in the tax region of 10 HTLV-1 carriersa  
  Number and type of single nucleotide substitution   Sequence context of G-to-A mutations 
  G-A C-T A-G A-C C-A G-C G-T T-A  GA GC GT GG 
C72 (24) 3         1   2 
C79 (24) 2 4  2 1 1      2  
C63 (21) 19            19 
C40 (21) 2            2 
C32 (25) 4 1           4 
C62 (27) 5 1         1  4 
C87 (24) 1 1        1    
C5 (26) 2            2 
C29 (25) 3  3     1     3 
C82 (22) 5      1      5 
Total 46 7 3 2 1 1 1 1  2 1 2 41 
aNumber of clones studied for each samples was indicated in the brackets. Mutated 
bases are underlined. 
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Table 6. Nonsense mutations in ten HTLV-1 carriers. 
Genes   pol   env   p12   p30/p13   p27a   tax   HBZ 
Position   3955 4540  5465 6158 6342 6362 6482 6494  -  7361  7652 7660  7469 8045  - 
C72   1/25 -/25   -/23 -/23 -/23 -/23 -/23 -/23   -/31   -/31   -/31 -/31   1/24 -/24   -/31 
C79  2/20 2/20  -/20 -/20 -/20 1/20 -/20 -/20  -/24  -/24  -/24 -/24  1/24 -/24  -/24 
C63  -/28 -/28  -/20 -/20 -/20 -/20 -/20 -/20  -/24  2/24  -/24 -/24  9/21 -/21  -/24 
C40  -/26 13/26  -/22 -/22 -/22 -/22 -/22 -/22  -/30  -/30  -/30 -/30  2/21 -/21  -/30 
C32  -/22 -/22  -/22 -/22 -/22 -/22 -/22 -/22  -/32  -/32  -/32 1/32  -/25 -/25  -/32 
C62  1/22 -/22  -/25 -/25 2/25 -/25 -/25 -/25  -/28  1/28  1/28  1/27 -/27  -/28 
C87  1/22 3/22  -/20 -/20 -/20 -/20 -/20 -/20  -/21  -/21  1/21 -/21  -/24 -/24  -/21 
C5  -/22 19/22  -/20 -/20 -/20 1/20 -/20 -/20  -/24  -/24  -/24 1/24  1/26 -/26  -/24 
C29  -/25 3/25  -/20 1/20 -/20 -/20 -/20 1/20  -/24  2/24  5/24 -/24  1/25 -/25  -/24 
C82   3/27 2/27   1/20 -/20 -/20 -/20 1/20 -/20   -/24   1/24   -/24 -/24   1/22 1/22   -/24 
Each entry A/B in the table shows the number A of clones harboring nonsense mutations 
at a given nucleotide position, from a given carrier, along with the number of clones B 
analyzed in that region from that carrier.  
aSequences of exon 2 were determined. 
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981 4540 4544 5026 5027 5028 5029 7242 7269 7324 7385 7400 7469 7566 7758
Standard G G A A A G G G A G G G G G C
Tumor A A G G G A A T G A C A A C T




Standard T G G
Tumor C A A























































































Site AGGA AGGC AGGT AGGG CGGA CGGC CGGT CGGG TGGA TGGC TGGT TGGG GGGA GGGC GGGT GGGG
Mutated 3 2 5 3 1 2 5 13 10 3 0 9 1 1 0 2
All 29 51 17 19 16 38 15 28 37 44 10 24 22 42 8 32

























































































































G-A C-T A-G T-C A-C A-T C-A C-G T-G Total
ATL-4 3(0) 4(1) 1 2 10
ATL-11 6(1) 9(1) 3 8 1 27
ATL-12 8(2) 8(1) 4 3 2 25
ATL-15 10(3) 6(2) 2 2 1 1 1 23
ATL-30 2(0) 1(0) 1 4
ATL-39 2(0) 8(0) 2 5 3 1 21
ATL-45 3(0) 3(0) 4 2 3 1 16
Figure 4
CCATGCTTATTATCAGCCCACTTCCCAGGGTTTGGACAGAGTCTTCTTTTCGGATACCCAGTCTACGTGTTTGGAGACTGTGTACAAGGCGATTGGTGCCCCAT   #  %
...........................A.....A....A.................................................................   8  13
.................................A.................A....................A...............A...............  12  20
.................................A.................A...................................A......A.........  19  32
............................AA...A....A............A..............A....................A......AA........  26  43













GA GG GC GT
























* P < 0.001
*
B
7291
Figure 5
